Iter-4360dd15-0124-transcript
第 124 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 erratum PMC4713958 corrected sentence original abstract"}) → call list_recent({"n":6})
→ call list_by_tag({"limit":10,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0123-transcript", "tags": "iteration transcript", "modified": "20260424220848000", "preview": "!! 第 123 轮执行轨迹
→ call search_memory({\\\"limit\\\":8,\\\"query\\\":\\\"4360dd15"}, {"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹 →"}, {"title": "Iter-4360dd15-0120-transcript", "tags": "iteration transcript", "modified": "20260424220420000", "preview": "!! 第 120 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0123-reflection", "modified": "20260424220853000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424220853000", "tags": "pinned focus"}, {"title": "先锁定原文再做修订对照", "modified": "20260424220853000", "tags": "lesson erratum verification evidence-chain"}, {"title": "Iter-4360dd15-0123-transcript", "modified": "20260424220848000", "tags": "iteration transcript"}, {"title": "BOLERO-2 erratum corrected abstract sentence", "modified": "20260424220843000", "tags": "fact 4360dd15 clinical-trials erratum evidence-chain"}, {"title": "Iter-4360dd15-0122-reflection", "modified": "20260424220712000", "tags": "iteration reflection"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "BOLERO-2 erratum corrected abstract sentence", "modified": "20260424220843000"}, {"title": "BOLERO-2 abstract should cite erratum-corrected subgroup wording", "modified": "20260424220656000"}, {"title": "BOLERO-2 erratum scope: subgroup wording only, PFS numerics unchanged", "modified": "20260424220522000"}, {"title": "BOLERO-2 erratum does not change abstract investigator-assessed PFS sentence or bibliographic metadata", "modified": "20260424220413000"}, {"title": "BOLERO-2 PMCID and abstract PFS sentence directly verified from PMC", "modified": "20260424220204000"}, {"title": "BOLERO-2 PMID PMCID DOI confirmed from Europe PMC and PMC", "modified": "20260424220045000"}, {"title": "BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export）", "modified": "20260424215916000"}, {"title": "BOLERO-2 主要终点具体结果数值（Springer OA）", "modified": "20260424215736000"}, {"title": "BOLERO-2 可访问非-NEJM 设计/终点证据已补齐", "modified": "20260424215252000"}, {"title": "BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核", "modified": "20260424215102000"}]}
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"BOLERO-2 erratum corrected abstract sentence"})
→ call read_note({"title":"BOLERO-2 abstract should cite erratum-corrected subgroup wording"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0123）\n\n直接提取并并排比对原摘要与 PMC4713958 中的修订句，确认应引用的精确一句话。"}
【tool:read_note】
{"ok": true, "title": "BOLERO-2 erratum corrected abstract sentence", "tags": "fact 4360dd15 clinical-trials erratum evidence-chain", "text": "!! BOLERO-2 erratum 的最终可引用摘要句\n\n来源：PMC4713958（Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis）\n\n''被更正的唯一摘要句末尾''：\n原句写作 “... in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and irrespective of age.”\n\n''修订后应引用的句子''：\n“Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38–0.54); log-rank P < 0.0001; central review: 11.0 versus 4.1 months, respectively; hazard ratio = 0.38 (95% confidence interval 0.31–0.48); log-rank P < 0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, and irrespective of age.”\n\n''关键差异''：\n- 删除了 “patients with recurrence during or within 12 months of completion of adjuvant therapy” 这一亚组表述。\n- 其余 PFS 数值、HR、CI、P 值未改。\n\n可复现核查：直接读取 PMC4713958 页面正文，搜索 “The correct sentence should read” 即可定位修订句。"}
【tool:read_note】
{"ok": true, "title": "BOLERO-2 abstract should cite erratum-corrected subgroup wording", "tags": "fact knowledge 4360dd15 clinical-trials erratum evidence-chain", "text": "!! 结论\n对于 BOLERO-2 这篇文章，若要引用摘要中的最终可用文本，应以 PMC4713958 所给出的 correct sentence 为准，而不是原始摘要句。\n\n!! 逐字对照结果\n原始摘要句在 “all prospectively defined subgroups” 后面列出：\n- “including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and irrespective of age.”\n\nerratum 将其改为：\n- “including patients with visceral metastases, and irrespective of age.”\n\n!! 影响范围\n- 被更正的是 subgroup wording。\n- “[investigator review: 7.8 versus 3.2 months ...; central review: 11.0 versus 4.1 months ...]” 这段 PFS 数值在 erratum 中 未改变。\n- 因此，若论证 PFS 结果，可继续使用原摘要/正文中的数值；若引用摘要里的分组表述，应采用更正后的版本。\n\n!! 可复现依据\n- Erratum 全文：PMC4713958\n- 原文条目入口：24158787（Europe PMC 记录）\n\n!! 最终表述建议\n当写成可引用的摘要转述时，优先写：\n''BOLERO-2 的 erratum 仅修正了摘要中的亚组措辞：应写作 “including patients with visceral metastases, and irrespective of age,” 而不应保留原先把 recurrence during or within 12 months of adjuvant therapy 也并入 prospectively defined subgroups 的表述。''"}
→ call web_search({"limit":5,"query":"BOLERO-2 final progression-free survival analysis abstract original PMID 22149876"})
→ call web_search({"limit":5,"query":"PMC4713958 erratum correct sentence should read BOLERO-2"})
→ call web_search({"limit":5,"query":"22149876 PubMed abstract BOLERO-2 everolimus exemestane final progression-free survival analysis"})
【tool:web_search】
{"ok": true, "query": "BOLERO-2 final progression-free survival analysis abstract original PMID 22149876", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "A total of 528 progression-free survival events were required for the final analysis , in order to detect a hazard ratio of 0.74 with 90% power with the use of a log-rank test and a two-look Lan ..."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population. Protocol-specified final PFS analyses are presented."}, {"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with ... - Springer", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A. Yardley • Shinzaburo Noguchi • Kathleen I. Pritchard Michael Gnant • Gabriel N. Hortobagyi • Mario Campone Bohuslav Melic
【tool:web_search】
{"ok": true, "query": "PMC4713958 erratum correct sentence should read BOLERO-2", "results": [{"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713958/", "snippet": "The correct sentence should read : Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38-0.54); log-rank P < 0.0001; central ..."}, {"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal ... - Europe PMC", "url": "https://europepmc.org/article/PMC/PMC4713958", "snippet": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis"}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1109653?articleTools=true", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival, with observed medians of 6.9 and 2.8 months, corresponding to a 57% ..."}, {"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://www.researchgate.net/publication/258044358_Erratum_to_Everolimus_Plus_Exemestane_in_Postmenopausal_Patients_wit
【tool:web_search】
{"ok": true, "query": "22149876 PubMed abstract BOLERO-2 everolimus exemestane final progression-free survival analysis", "results": [{"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than t
→ call search_memory({"limit":10,"query":"4360dd15 24158787 original abstract sentence BOLERO-2 recurrence during or within 12 months"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0113-transcript", "tags": "iteration transcript", "modified": "20260424215108000", "preview": "!! 第 113 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 BOLERO-2 PMID 22149876 primary endpoint trial design accessible authority\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0094-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424210844000\", \"preview\": \"!! 第 94 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 BOLERO-2 erratum abstract corrected sentence PMC4713958 investigator assessed PFS\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0120-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424220420000\", \"preview\": \"!! 第 120 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 BOLERO-2 PMID original human trial primary endpoint\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:searc → call web_fetch({"max_chars":8000,"url":"https://europepmc.org/article/MED/24158787"})
→ call web_fetch({"max_chars":8000,"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713958/"})
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/24158787", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
→ call web_search({"limit":10,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract"})
→ call web_search({"limit":10,"query":"\"10.1007/s12325-013-0060-1\" abstract BOLERO-2"})
→ call web_search({"limit":10,"query":"site:link.springer.com 10.1007/s12325-013-0060-1 abstract"})
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "ABSTRACT Introduction: positive (HR?) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy . Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III tria [ abstract ]."}, {"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer [ abstract ]."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-with-Yardley-Noguchi/18628012e9bd5552cb865900148821bee522c82c", "snippet": "The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs, and results further support the use ofEverolimus plus exemstane in this patient population. Intro
【tool:web_search】
{"ok": true, "query": "\"10.1007/s12325-013-0060-1\" abstract BOLERO-2", "results": []}
【tool:web_search】
{"ok": true, "query": "site:link.springer.com 10.1007/s12325-013-0060-1 abstract", "results": []}
→ call web_fetch({"max_chars":9000,"url":"https://link.springer.com/article/10.1007/s12325-013-0060-1"})
→ call web_fetch({"max_chars":9000,"url":"https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf"})
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis | Advances in Therapy | Springer Nature Link Skip to main content Advertisement Log in Menu Find a journal Publish with us Track your research Search Saved research Cart Home Advances in Therapy Article Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Original Research Open access Published: 25 October 2013 Volume 30 , pages 870–884, ( 2013 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Advances in Therapy Aims and scope Submit manuscript Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Download PDF Denise A. Yardley 1 , Shinzaburo Noguchi 2 , Kathleen I. Pritchard 3 , Howard A. Burris III 1 , José Baselga 4 , Michael Gnant 5 , Gabriel N. Hortobagyi 6 , Mario Campone 7 , Barbara Pistilli 8 , Martine Piccart 9 , Bohuslav Melichar 10 , Katarina Petrakova 11 , Francis P. Arena 12 , Frans Erdkamp 13 , Wael A. Harb 14 , Wentao Feng 15 , Ayelet Cahana 15 , Tetiana Taran 15 , David Lebwohl 15 & … Hope S. Rugo 16 Show authors 24k Accesses 492 Citations 41 Altmetric 2 Mentions Explore al
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "status": 200, "content_type": "application/pdf", "text": "%PDF-1.4\r%����\r\n231 0 obj\r<</Linearized 1/L 517515/O 234/E 194693/N 15/T 512774/H [ 2096 1101]>>\rendobj\r \r\nxref\r\n231 90\r\n0000000016 00000 n\r\n0000003197 00000 n\r\n0000003365 00000 n\r\n0000003401 00000 n\r\n0000003956 00000 n\r\n0000004119 00000 n\r\n0000005064 00000 n\r\n0000006229 00000 n\r\n0000006401 00000 n\r\n0000007567 00000 n\r\n0000008469 00000 n\r\n0000008633 00000 n\r\n0000008736 00000 n\r\n0000008773 00000 n\r\n0000009651 00000 n\r\n0000009790 00000 n\r\n0000010428 00000 n\r\n0000011330 00000 n\r\n0000012497 00000 n\r\n0000013664 00000 n\r\n0000013720 00000 n\r\n0000027228 00000 n\r\n0000028549 00000 n\r\n0000029249 00000 n\r\n0000029888 00000 n\r\n0000031054 00000 n\r\n0000032166 00000 n\r\n0000032329 00000 n\r\n0000032470 00000 n\r\n0000033290 00000 n\r\n0000045052 00000 n\r\n0000045106 00000 n\r\n0000046158 00000 n\r\n0000046795 00000 n\r\n0000047960 00000 n\r\n0000048041 00000 n\r\n0000048462 00000 n\r\n0000049433 00000 n\r\n0000049472 00000 n\r\n0000050019 00000 n\r\n0000050153 00000 n\r\n0000093441 00000 n\r\n0000093741 00000 n\r\n0000093794 00000 n\r\n0000093895 00000 n\r\n0000094127 00000 n\r\n0000095139 00000 n\r\n0000096303 00000 n\r\n0000097203 00000 n\r\n0000098030 00000 n\r\n0000098857 00000 n\r\n0000108317 00000 n\r\n0000109273 00000 n\r\n0000111966 00000 n\r\n0000115264 00000 n\r
→ call write_note({"tags":["fact","lesson","4360dd15","erratum","evidence-chain","critic"],"text":"!! BOLERO-2 erratum: exact abstract sentence and what it does //not// change\n\n!! 原摘要句（错误版）\n“Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; )
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\BOLERO-2_erratum_exact_abstract_sentence_and_boundary_of_correction.tid", "title": "BOLERO-2 erratum exact abstract sentence and boundary of correction"}
【assistant】
本轮已完成：并排核对了 BOLERO-2 原摘要与 PMC4713958 erratum 修订句，确认更正只删掉了“patients with recurrence during or within 12 months of completion of adjuvant therapy”这段亚组措辞，PFS 数值/HR/CI/P 值未变。
我已把这一点写入长期记忆，并明确了当前最容易出错的边界：不要把摘要更正误扩展到全文结果或方法定义。
<NEXT_FOCUS>验证被删掉的 recurrence 语句是否仍然只存在于方法中的入组/疾病定义，而不是作为“prospectively defined subgroups”出现在结果摘要里。</NEXT_FOCUS>